Molecular Partners AG American Depositary Shares (MOLN)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Molecular Partners through a Graham lens, and the first question is survival, not excitement. It is a clinical-stage biotech with 134 employees, developing DARPin therapeutics; MP0317 is in Phase 2, MP053 in Phase 1, and MP0712 is a radio-DARPin candidate. That pipeline is the only real asset, but it is not a moat yet. No marketed product is listed in the data, and no revenue growth figure is supplied. The balance sheet has one comfort: debt to equity is just 0.05. But the income statement is ugly. FairStock calculates a P/E of -2.25 and a P/B of 1.96 using the 2026-10-13 close of $3.67. ROE is -61.97% and ROCE is -32.27%. Trailing free cash flow is -$46.3M, a negative 27.8% FCF yield on the $166.5M market cap. Piotroski is 0/9 and Altman Z is 0.60. Those are not the marks of a bargain; they are distress signals. The stock sits near its 52-week low of $3.53, with a 52-week high of $5.36 and a beta of 0.69. FairStock assigns no Lynch category because there are only 0 years of filed results, below the required 3. Without revenue or earnings to anchor value, the price is a speculation on clinical data. Graham would demand a margin of safety in proven assets and earnings; Buffett would want a durable moat and predictable cash flows. Molecular Partners offers neither today. The low debt helps, but book value in biotech can vanish in failed trials.

In plain English: Molecular Partners is a clinical-stage biotech that designs protein-based drugs for cancer and leukemia. The business looks weak and risky because it is still testing its drugs in trials, loses money, and burns cash. At $3.67, the price is hard to judge as cheap since there are no profits to value it against; it looks speculative rather than a stable bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer